Short reportVancomycin (cas 1404-90-6) use in surrounding patients during critical illness and risk for persistent colonization with Vancomycin (cas 1404-90-6)-resistant Enterococcus

Add time:09/07/2019    Source:sciencedirect.com

SummaryThe optimal duration of contact precautions for vancomycin-resistant enterococcus (VRE)-colonized patients is uncertain and individual patient characteristics alone may not predict risk of prolonged colonization. Using a cohort of adult patients who underwent testing for VRE at intensive care unit (ICU) admission, we tested the association between local (unit-level) vancomycin use and persistent colonization with VRE. Higher unit-level vancomycin use significantly prolonged VRE colonization (P=0.03) independent of patient-level vancomycin use and unit VRE density.

We also recommend Trading Suppliers and Manufacturers of Vancomycin (cas 1404-90-6). Pls Click Website Link as below: cas 1404-90-6 suppliers

Prev:Vancomycin (cas 1404-90-6) release from biodegradable βTCP-FeAg nanocomposites
Next:ReviewThe dosing and monitoring of Vancomycin (cas 1404-90-6): what is the best way forward?)